HCPLive

Dr. Kimme Hyrich Discusses Cancer Risk in RA Patients Receiving Anti-TNF Therapies

$shareThis$
Kimme L. Hyrich, MD, Arthritis Research UK Epidemiology Unit at University of Manchester, discusses the risk of rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy developing solid cancers.

“When they were first used and available for widespread use, there was a continuing anxiety about whether or not an agent which blocks tumor necrosis factor would actually increase the risk of cancer in patients with rheumatoid arthritis,” said Hyrich.

Most Popular

Recommended Reading

The ARTEMIS device provides a new perspective for urologists and patients alike when looking at potential prostate cancer patients.
Using the ARTEMIS device may take a little longer than the traditional MRI for prostate cancer, but with more rapid results and easier to read monitors for the patients and doctors, the results show real benefit in overall diagnosis.
For many years traditional ultrasound has been the main method of diagnosing prostate cancer. In recent years new developments in technology have provided a more effective and efficient method that can provide nearly instantaneous results.
About 6.1 percent of U.S. allopathic medical school seniors in the National Resident Matching Program (NRMP) were not placed into first-year residency positions, with a higher percentage of unmatched seniors than in 2014, according to a report published by the American Medical Association.

$vacMongoViewPlus$ $vAR$